家蝇幼虫血淋巴中抗真菌肽的诱导方法比较及抗真菌活性

以未诱导组作为空白对照研究比较真菌诱导、超声诱导和热诱导家蝇Musca domestica 幼虫血淋巴初提液的抗真菌肽效果,比较各种诱导方法诱导后的幼虫存活率;用凝胶层析法和高效液相分离纯化热诱导家蝇3龄幼虫抗真菌肽,检测其抗白假丝酵母菌Candida albicans和新生隐球菌Cryptococcus neoformans活性;SDS-PAGE分析抗真菌肽的蛋白分子量范围。结果表明：3种诱导方法诱导后家蝇幼虫均产生具有明显抗真菌作用的抗真菌肽,其初提液抑菌圈大小没有明显差别;真菌诱导组和热诱导组幼虫存活率低于对照组,而超声诱导组与对照组相比则无明显差别。经分离纯化后,抗真菌肽仍具有较好的抗真菌活性;SDS-PAGE分析表明该抗真菌肽有效成分的蛋白分子量在14.4 kD以下。结果提示热诱导家蝇幼虫产生抗真菌肽是一种方便、有效的诱导方式。     

家蝇抗真菌肽-溶菌酶基因的克隆、表达及序列分析

旨在对家蝇抗真菌肽MAF-1-溶菌酶(LZM)基因进行生物信息学分析,并进行融合基因MAF-1-LMZ的克隆和表达分析。从Gen Bank获得家蝇抗真菌肽MAF-1和溶菌酶LZM的编码序列,分析和预测这两种蛋白质的结构和功能。PCR扩增融合蛋白质抗真菌肽-溶菌酶的基因MAF-1-LMZ,将其克隆到原核表达载体p ET-28a中,重组质粒p ET-28a-MAF-1-LMZ在大肠杆菌Origmi B/DE3中经用IPTG诱导表达,表达产物MAF-1-LMZ通过SDS-PAGE电泳进行鉴定,采用小试管法倍比稀释法进行活性验证。结果显示,融合蛋白质MAF-1-LMZ序列的ORF为969 bp,编码322个氨基酸残基,理论分子量为35 468.6 Da,等电点为8.31,在大肠杆菌Origmi B/DE3中得到成功表达。其纯化后的目的蛋白具有抗真菌活性。     

家蝇抗菌肽基因MAF-1的表达模式及响应微生物刺激分析

Musca domestica antifungal peptide-1(MAF-1)是家蝇体(Musca domestica)内组成型表达的一种独特且具有良好抑菌效果的抗真菌肽.本研究利用实时荧光定量PCR技术分析MAF-1在家蝇不同发育时期、不同组织器官及家蝇3龄幼虫经微生物(大肠杆菌、金黄色葡萄球菌和白色念珠菌)刺激后的表达特征.结果显示,MAF-1在家蝇各个发育时期的相对表达量依次为:2龄幼虫＞1龄幼虫＞3龄幼虫＞雄蝇成虫＞卵＞雌蝇成虫＞蛹;MAF-1在家蝇3龄幼虫各组织器官的相对表达量依次为:脂肪体＞唾液腺＞气管＞肠道＞体壁.通过超微量显微注射法向家蝇3龄幼虫体内注入病原微生物,其中金黄色葡萄球菌刺激后MAF-1的表达量呈下降趋势;大肠杆菌刺激后MAF-1的表达量先降低后升高再降低;白色念珠菌刺激后MAF-1的表达量先升高然后逐渐下降.本研究从RNA水平上说明了MAF-1的表达随着家蝇幼虫的生长发育阶段变化,对不同微生物刺激的响应具有不同的特征.同时MAF-1还是家蝇抵抗病原微生物感染的重要天然免疫分子,这为进一步研究其参与家蝇天然免疫防御过程提供了基础.     

家蝇抗菌肽基因MAF-1的表达模式及响应微生物刺激分析

Musca domestica antifungal peptide-1(MAF-1)是家蝇体(Musca domestica)内组成型表达的一种独特且具有良好抑菌效果的抗真菌肽.本研究利用实时荧光定量PCR技术分析MAF-1在家蝇不同发育时期、不同组织器官及家蝇3龄幼虫经微生物(大肠杆菌、金黄色葡萄球菌和白色念珠菌)刺激后的表达特征.结果显示,MAF-1在家蝇各个发育时期的相对表达量依次为:2龄幼虫＞1龄幼虫＞3龄幼虫＞雄蝇成虫＞卵＞雌蝇成虫＞蛹;MAF-1在家蝇3龄幼虫各组织器官的相对表达量依次为:脂肪体＞唾液腺＞气管＞肠道＞体壁.通过超微量显微注射法向家蝇3龄幼虫体内注入病原微生物,其中金黄色葡萄球菌刺激后MAF-1的表达量呈下降趋势;大肠杆菌刺激后MAF-1的表达量先降低后升高再降低;白色念珠菌刺激后MAF-1的表达量先升高然后逐渐下降.本研究从RNA水平上说明了MAF-1的表达随着家蝇幼虫的生长发育阶段变化,对不同微生物刺激的响应具有不同的特征.同时MAF-1还是家蝇抵抗病原微生物感染的重要天然免疫分子,这为进一步研究其参与家蝇天然免疫防御过程提供了基础.     

家蝇抗菌肽基因MAF-1的表达模式及响应微生物刺激分析

Musca domestica antifungal peptide-1(MAF-1)是家蝇体(Musca domestica)内组成型表达的一种独特且具有良好抑菌效果的抗真菌肽.本研究利用实时荧光定量PCR技术分析MAF-1在家蝇不同发育时期、不同组织器官及家蝇3龄幼虫经微生物(大肠杆菌、金黄色葡萄球菌和白色念珠菌)刺激后的表达特征.结果显示,MAF-1在家蝇各个发育时期的相对表达量依次为:2龄幼虫＞1龄幼虫＞3龄幼虫＞雄蝇成虫＞卵＞雌蝇成虫＞蛹;MAF-1在家蝇3龄幼虫各组织器官的相对表达量依次为:脂肪体＞唾液腺＞气管＞肠道＞体壁.通过超微量显微注射法向家蝇3龄幼虫体内注入病原微生物,其中金黄色葡萄球菌刺激后MAF-1的表达量呈下降趋势;大肠杆菌刺激后MAF-1的表达量先降低后升高再降低;白色念珠菌刺激后MAF-1的表达量先升高然后逐渐下降.本研究从RNA水平上说明了MAF-1的表达随着家蝇幼虫的生长发育阶段变化,对不同微生物刺激的响应具有不同的特征.同时MAF-1还是家蝇抵抗病原微生物感染的重要天然免疫分子,这为进一步研究其参与家蝇天然免疫防御过程提供了基础.     

致念珠菌性包皮龟头炎白假丝酵母菌对9种抗真菌药物最低抑菌浓度测定

目的检测引起念珠菌性包皮龟头炎的白假丝酵母菌对9种抗真菌药物MIC,为临床治疗念珠菌性包皮龟头炎提供参考依据。方法常规培养分真菌,并鉴定到种,采用最低抑菌浓度法对白假丝酵母菌进行体外药物敏感试验。结果培养分离的12株菌中,白假丝酵母菌占75.00%,白假丝酵母菌生物变种占16.67%,近平滑假丝酵母菌占8.33%;11株白假丝酵母菌耐药率由高到低依次是氟康唑,伊曲康唑,咪康唑,酮康唑,克霉唑,益康唑,5-氟胞嘧啶啶,两性霉素B,制霉菌素,其中6种药物耐药率大于50%。结论白假丝酵母菌仍是造成念珠菌性包皮龟头炎最常见的致病菌,耐多药现象较为普遍,应根据临床实验室的体外药敏试验结果,指导临床合理用药。     

家蝇抗真菌肽衍生物MAF-1C抗白色念珠菌活性研究

[目的]探究家蝇抗真菌肽衍生物MAF-1C结构特点及抗白色念珠菌活性。[方法]采用氨基酸替代法设计MAF-1A衍生肽MAF-1C,生物信息学分析其理化特性,微量液体稀释法、菌落计数法检测体外抗白色念珠菌活性,扫描电镜观察对菌细胞结构的影响。[结果]MAF-1C为非跨膜阳离子线状多肽,带8个正电荷,二级结构以α螺旋为主。对白色念珠菌具有抗菌活性,MIC、MFC值分别为0.2 mg/m L和0.5 mg/m L,2×MIC浓度的MAF-1C从作用一开始就发挥抗菌作用,其作用后白色念珠菌细胞表面出现明显的凹陷、裂痕,之后细胞皱缩、裂解死亡,并且菌细胞损伤程度与肽浓度及作用时间呈正相关。[结论]MAF-1C结构参数及对白色念珠菌的抗菌活性均显著优于模板肽,对比模板肽改造后的肽阳离子电荷增加了6个,总平均疏水值(GRAVY)由-1.081升高到0.588,不稳定系数由42.27降低到5.83,MIC由0.6 mg/m L降低到0.2 mg/m L,MFC由0.7 mg/m L降低到0.5 mg/m L,其可通过破坏白色念珠菌细胞结构发挥抗菌作用。     

不同诱导条件下家蝇(Musca domestica)三龄幼虫免疫相关基因的表达研究

旨在研究在不同诱导条件下家蝇三龄幼虫先天性免疫基因的表达情况。采用冷刺激、热刺激及革兰氏阴性菌、革兰氏阳性菌和真菌注射诱导12 h后提取家蝇三龄幼虫总RNA。根据GenBank公布的家蝇磷酸甘油醛脱氢酶(GAPDH)基因、攻击素(Attacin)、天蚕素(Cecropin)、防御素(Defensin)、双翅肽(Diptericin)、溶菌酶(Lysozyme)、热休克蛋白(Heat shock protein,HSP)及家蝇抗真菌肽(MAF-1)基因序列进行RT-PCR反应,以GAPDH基因为内参照,分析在不同诱导条件下家蝇三龄幼虫先天性免疫基因的表达情况。结果显示,不同条件诱导下,家蝇免疫相关基因表达显现较大差异,微生物诱导比物理刺激诱导后家蝇免疫相关基因表达水平高;真菌、阳性菌诱导后家蝇免疫相关基因表达量最高,阴性菌次之;冷刺激诱导最低。微生物及物理刺激均能激活家蝇的免疫系统,在不同条件刺激下,家蝇幼虫机体免疫应激反应不同。     

医院内假丝酵母菌感染菌种的分布及耐药分析

目的了解医院内假丝酵母菌感染菌种的分布及抗真菌药物的耐药谱,为临床抗真菌治疗提供正确数据。方法采用VITEK-32微生物自动鉴定仪进行假丝酵母菌菌种的鉴定,同时用ATB FUNGUS真菌药敏条作药敏试验。结果从住院患者的血液、痰、尿、分泌物、胆汁等标本中共检出真菌505株。其中白假丝酵母菌281株,热带假丝酵母菌124株,光滑假丝酵母菌21株,季也蒙假丝酵母菌17株,近平滑假丝酵母菌16株,克柔假丝酵母菌10株,皱折假丝酵母菌8株,异常汉逊假丝酵母菌6株,5氟-胞嘧啶和两性霉素抑菌效果最好,其耐药率分别为2.8%和3.4%。其他4种抗真菌药物制霉菌素、氟康唑、伊曲康唑和酮康唑的耐药率分别为6.1%、13.7%、9.3%和28.3%。结论医院假丝酵母菌感染耐药率逐年上升,非白假丝酵母菌感染明显增加。氟康唑对白假丝酵母菌有很强的抗菌活性且毒副作用小。假丝酵母菌感染的迅速增加同广泛应用超广谱抗菌药物、激素及免疫抑制剂等有关。假丝酵母菌感染死亡率高,因此早期诊断及有效性治疗是减少死亡率的关键。     

血流感染真菌的分布及耐药性分析

目的了解真菌性血液感染常见病原真茵的菌群分布及耐药性状况,为临床真菌感染性疾病提供病原学诊断和合理使用抗真菌药物的依据。方法回顾性分析浙江大学医学院附属第一医院5年（2008-2012年）间导致真菌性血液感染的217株真菌的菌群分布及药物敏感性状况。结果217株真菌标本中以假丝酵母菌属为主,占88. 5%;其中又以白假丝酵母菌比例最高,占35.4%。菌种分布与患者的性别和年龄存在相关性。60-79岁年龄组感染白假丝酵母菌多见,占49% ,这一比例明显高于其他真菌。男性更容易感染白假丝酵母菌（40.1% vs 24.6%,P〈0.05）,女性感染近平滑假丝酵母菌更常见（24.6% vs 11.8%,P〈0.05）.假丝酵母菌和新生隐球菌对两性霉素B、伏立康唑、氟康唑、伊曲康唑、5-氟胞嘧啶的敏感性均较高。光滑假丝酵母菌对伊曲康唑敏感率较低,仅为60.0%。结论真菌血流感染在临床呈上升趋势,抗真菌药物均体现较高抗菌活性,对真菌感染进行地区层面流行病学调查和耐药监测很重要。     

Antifungal activities of recombinant antifungal protein by conjugation with polyethylene glycol.

Tenecin 3, an antifungal protein isolated from coleopteran insect Tenebrio molitor larvae, inhibited growth of the fungus Candida albicans. We have previously reported that tenecin 3 has a propensity of random structure with very loose turn-like elements by circular dichroism (CD) analysis and 2D nuclear overhauser effect spectroscopy [Lee et al. (1999)]. However, the antifungal mechanism of tenecin-3 has not yet been studied due to its very low availability from natural sources. As an initial step to study the antifungal mechanism of tenecin 3, recombinant tenecin 3 (RT-3) obtained from an expression system in Escherichia coli showed antifungal activity against C. albicans as did natural tenecin 3. To elucidate the antifungal mechanism of RT-3 and to explore the possibility of preparing polyethylene glycol (PEG) conjugated derivative, we synthesized PEG conjugated RT-3 (RT-3-PEG) and examined its antifungal activity against C. albicans in vitro. RT-3-PEG showed greater antifungal activity against C. albicans than RT-3 alone at the same dose. When C. albicans was treated with RT-3-PEG in vitro, K+ in the C. albicans cell was leaked out rapidly compared to the C. albicans treated with RT-3 alone. When the morphological change of RT-3-PEG treated C. albicans was examined by scanning electron microscopy, string-like substances, which may have been derived from the fungus, were stacked around the cell whose wall was damaged. Also, no appreciable hemolysis of mouse erythrocytes was detected under conditions in which 1% melittin caused 100% hemolysis. These results suggested that the RT-3-PEG derivative probably does not interact with mammalian cell appreciably, although it has antifungal activity.     

Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents

A series of 1-(substituted biaryloxy)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl) propan-2-ol were synthesized and their antifungal activities were evaluated against eight human pathogenic fungi in vitro. Seventeen compounds showed activity 4- to 64-fold higher than voriconazole against Candida albicans. SAR clearly suggested that introduction of a biaryloxy side chain greatly enhanced the antifungal activity of triazole analogs against Candida species.     

Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51)

A series of fluconazole (1) analogues, compounds 3a-k, were prepared as potential antifungal agents. They were designed by computational docking experiments to the active site of the cytochrome P450 14alpha-sterol demethylase (CYP51), whose crystal structure is known. Preliminary biological tests showed that most of the target compounds exhibit significant activities against the eight most-common pathogenic fungi. Thereby, the most potent congener, 1-[(4-tert-butylbenzyl)(cyclopropyl)amino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (3j), was found to exhibit a broad antifungal spectrum, being more active against Candida albicans, Candida tropicalis, Cryptococcus neoformans, Microsporum canis, and Trichophyton rubrum (MIC80 < 0.125 microg/ml) than the standard clinical drug itraconazole (2). The observed affinities of the lead molecules towards CYP51 indicate that a cyclopropyl residue enhances binding to the target enzyme. Our results may provide some guidance for the development of novel triazole-based antifungal lead structures.     

2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents

2-Hydroxyphenacyl azole and 2-hydroxyphenacyl azolium compounds have been described as a new class of azole antifungals. Most target compounds showed significant in vitro antifungal activities against tested fungi (Candida albicans, Saccharomyces cerevisiae, Aspergillus niger, and Microsporum gypseum) with low MICs values included in the range of 0.25-32 microg/mL comparable to reference drug fluconazole. The most active compounds were also assessed for their cytotoxicity using MTT colorimetric assay on normal mouse fibroblast (NIH/3T3) cells. The results of antifungal activity and toxicity tests indicated that these compounds display antifungal activity at non-cytotoxic concentrations.     

Isolation, characterization and antifungal activity of Streptomyces sampsonii GS 1322

For new antifungal antibiotics from actinomycetes, a strain of Streptomyces GS 1322 was isolated from a sample of garden soil. The strain was found to possess antagonistic activity against four fungi i.e., Candida albicans, Aspergillus niger, Microsporum gypseum and Trichophyton sp. The strain was identified as Streptomyces sampsonii and the antifungal compound produced by it was found to be the heptaene group of polyene antibiotics.     

Production of heptaene antifungal antibiotic by Streptomyces purpeofuscus CM 1261

A strain of Streptomyces purpeofuscus CM 1261 isolated from a sample of compost collected locally was found to possess strong antagonistic activity against 4 human pathogenic fungi i.e., Candida albicans, Aspergillus niger, Microsporum gypseum and Trichophyton sp. The active antifungal compound produced by it was found to be a heptaene group of polyene antifungal antibiotic.     

Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide.

Vasostatin-I, the natural fragment of chromogranin A-(1-76), is a neuropeptide able to kill a large variety of fungi and yeast cells in the micromolar range. We have examined the antifungal properties of synthetic vasostatin-I-related peptides. The most active shortest peptide, named chromofungin, corresponds to the sequence Arg(47)-Leu(66). Extensive (1)H NMR analysis revealed that it adopts a helical structure. The biophysical mechanism implicated in the interaction of chromofungin with fungi and yeast cells was studied, showing the penetration of this peptide with different lipid monolayers. In order to examine thoroughly the antifungal activity of chromofungin, confocal laser microscopy was used to demonstrate the ability of the rhodamine-labeled peptide to interact with the fungal cell wall, to cross the plasma membrane, and to accumulate in Aspergillus fumigatus, Alternaria brassicola, and Candida albicans. Our present data reveal that chromofungin inhibits calcineurin activity, extending a previous observation that the N-terminal region of chromogranin A interacts with calmodulin in the presence of calcium. Therefore, the destabilization of fungal wall and plasma membrane, together with the possible intracellular inhibition of calmodulin-dependent enzymes, is likely to represent the mechanism by which vasostatin-I and chromofungin exert antifungal activity.     

The comparison of characteristics between membrane-active antifungal peptide and its pseudopeptides

By the introduction of various amide surrogates, novel pseudopeptides corresponding to a membrane active depsipeptide were synthesized and their native characteristics compared with that of the peptide. The pseudopeptides had more resistance to serum proteases than the peptide and similar antimicrobial activities to that of the peptide without hemolytic activity. The pseudopeptides like the peptide were active against current drug resistant fungi and pathogenic fungi isolated from patients, and also had a strong synergism with current antifungal drugs against Candida albicans. The leakage assay suggested that the pseudopeptides also acted on the lipid membrane of pathogenic cells. These results indicated that the novel pseudopeptides had advantages over the peptide as a candidate for a novel antifungal drug and backbone modifications can be a tool in the development of a novel antifungal agent from membrane-active peptides isolated from natural sources or chemically synthesized.     

美浮特皮肤抗菌液对致足癣真菌抗真菌后效应的体外研究

目的：评价美浮特^R皮肤抗菌液对致足癣真菌皮肤癣菌和白念珠菌的体外抗真菌活性及抗真菌后效应。方法采用美国 CLSI M27-A3和 M38-A2方案测定美浮特皮肤抗菌液对足癣常见致病真菌的最低抑菌浓度（ MIC）;并以白念珠菌（ATCC90028）为指示菌测定美浮特皮肤抗菌液测定时间-杀菌曲线,同时测定其对白念珠菌的抗真菌后效应（post-antifungal effect,PAFE）。结果美浮特皮肤抗菌液对4属6种57株 MIC 的范围为1：40-1：160、MIC50为1：80、MIC90为1：40;对白念珠菌的 MIC 范围为1：40-1：80、对皮肤癣菌的 MIC 范围为1：40-1：160。该抗菌液具有很强的杀菌作用,且随着药物浓度的降低,杀菌速度和程度随之变化。该抗菌液对白念珠菌0.5MIC、MIC、2MIC 的 PAFE 分别为0.85 h、2.1 h、3.59 h;且 PAFE 时间的延长与药物浓度呈正相关。结论美浮特^R皮肤抗菌液对致病真菌皮肤癣菌、白念珠菌具有快速、有效、持续的杀菌作用,该抗菌液对皮肤癣菌较白念珠菌具有更强的抗真菌作用。且该抗菌液对白念珠菌具有较长时间的后效应,可以广泛应用于临床治疗皮肤癣菌及白念珠菌所致的感染。     

In vitro antifungal activity of anidulafungin

Anidulafungin is a new and very useful pharmacological tool for the treatment of invasive mycoses. The antifungal spectrum of anidulafungin reaches the most common pathogenic fungi. Anidulafungin is especially active against the genera Candida and Aspergillus. Its antifungal mechanism is based on the inhibition of the beta-1,3-D-glucan synthesis, an essential molecule for the cell wall architecture, with different consequences for Candida and Aspergillus, being anidulafungin fungicide for the former and fungistatic for the latter. This review describes the in vitro antifungal spectrum of anidulafungin based in the scientific and medical literature of recent years. We can underline that most than 99% of Candida isolates are susceptible to < or = 2 microg/ml of anidulafungin. MIC are very low (< or =0.125 microg/ml) for most clinical isolates of the species Candida albicans, Candida glabrata, Candida tropicalis and Candida krusei while Candida parapsilosis and Candida guilliermondii isolates are susceptible to anidulafungin concentrations < or = 2 microg/ml. An excellent activity of anidulafungin has been also described against Aspergillus, Pneumocystis and other fungi. However, its activity is very low against Cryptococcus and the Zygomycetes. The excellent activity of anidulafungin has made this antifungal a first line therapeutic indication for candidemia and invasive candidiasis in non-neutropenic patients.